AzTrials
AzTrials

DiabetesNCT02961088

Meta-analyses of Pasta as Part of Low Glycemic Index Diets and Adiposity

An observational study of Diabetes and Prediabetes, run by University of Toronto.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Pasta is an important example of a food which can lower the glycemic index (GI) of the diet, a property that has been exploited extensively in studies of low GI dietary patterns. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Diabetes, Prediabetes, Overweight
What is being tested?
Pasta as part of a low GI/GL diet
How many people
1 participants
Where
No sites listed yet
Study dates
Aug 2016to Aug 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: All individuals, with the exception of children and pregnant or breast-feeding women, regardless of health status.

Who may be able to join

  • Dietary trials in humans
  • Randomized trials
  • Trials greater than or equal to 3 weeks duration
  • Suitable control group
  • Viable outcome data

Who cannot join

  • No assessment of the glycemic index
  • Co-intervention present (i.e. the study is designed in such a way that the effect of past as part of a low glycemic index or glycemic load diet can not be isolated)
  • Trials looking at the glycemic index of specific foods instead of the diet as a whole
  • Trials that did not include pasta as part of the low GI/GL diet
  • Trials that included pasta in the control diet
  • Trials including pregnant or breast feeding women
Show all 11Show fewer
  • Non-human studies
  • Non-randomized trials
  • Trials less than 3 weeks duration
  • Lack of a suitable control group
  • No viable endpoint data

About this study

Official title: Effect of Pasta as Part of Low Glycemic Index Diets on Body Weight and Markers of Adiposity in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development

Pasta is an important example of a food which can lower the glycemic index (GI) of the diet, a property that has been exploited extensively in studies of low GI dietary patterns. Although low-GI dietary patterns have been shown to improve body weight, glycemic control and blood lipids, it is unclear whether pasta as part of low-GI dietary patterns will improve measures of global adiposity including body weight. The lack of high quality knowledge syntheses to support evidence-based dietary guidance of the cardiometabolic benefits of pasta represents an urgent call for stronger evidence. To improve evidence-based guidance for pasta recommendations, the investigators propose to conduct a systematic review and meta-analysis of controlled studies in humans to assess the effect of eating pasta as part of a low GI diet compared to other diets on measures of adiposity (body fatness) in humans. The systematic review process allows the combining of the results from many studies in order to arrive at a pooled estimate, similar to a weighted average, of the true effect. The investigators will be able to explore whether eating pasta as part of a low GI diet has different effects between men and women, in different age groups and in people with high or normal sugar. The findings of this proposed knowledge synthesis will help improve the health of Canadians through informing recommendations for the general public, as well as those at risk of heart disease and diabetes.

Read the detailed description

Background: Overweight and obesity is a key modifiable risk factor for the prevention and management of type 2 diabetes, dyslipidemia, hypertension, CVD and certain cancers. Low-GI dietary patterns have been shown to improve body weight, among other risk factors including glycemic control and blood lipids, and have been associated with risk reduction of type 2 diabetes and CVD. Current clinical practice guidelines suggest the replacement of high GI foods with low GI foods for improvement of glycemic control and cardiovascular risk factors. Pasta is an important example of a food which can lower the GI of the diet, a property that has been exploited extensively in studies of low GI dietary patterns. However, it is unclear whether pasta as part of low-GI dietary patterns will improve measures of global adiposity, including body weight in addition to other markers of adiposity.

Need for a review: The lack of high quality knowledge syntheses to support evidence-based dietary guidance on pasta represents an urgent call for stronger evidence. A systematic review and meta-analysis of randomized controlled trials remains the "Gold Standard" of evidence to support clinical practice guidelines and public health policy. By pooling the totality of the available evidence, a systematic reviews and meta-analyses of randomized controlled trials would provide the best estimate of the effect of pasta on measures of global adiposity relevant to the prevention and management of overweight and obesity.

Objectives: To provide evidence-based guidance for public health policy, health claims, and nutrition guidelines relating to pasta as part of low GI dietary pattern, the investigators will conduct a systematic review and meta-analysis of randomized controlled trials to assess the effect of past as part of a low GI diet on markers of global adiposity, including body weight in addition to others as well as regional markers of adiposity which have demonstrated clinical relevance.

Design: The planning and conduct of the proposed meta-analyses will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.

Data sources: MEDLINE, EMBASE and The Cochrane Central Register of Controlled Trials will be searched using appropriate search terms.

Study selection: Randomized controlled trials that investigate the effect of pasta as part of a low GI dietary pattern on body weight and other markers of adiposity in humans will be included. Trials that are less than 3 weeks diet duration, do not have a control group, include pregnant women, breast feeding women or children, or do not report data on markers of body weight will be excluded.

Data extraction: Two independent investigators will extract information about study design, sample size, subject characteristics, GI/GL diet, follow-up, and the composition of the background diets. Mean ± SEM values will be extracted for all outcomes. Standard computations and imputations will be used to derive missing data. Risk of bias will be assessed using the Cochrane Collaboration risk of bias tool.

Outcome: The primary outcome will be mean differences in body weight as a global marker of adiposity which has demonstrated clinical relevance. Secondary outcomes will be mean differences in other markers of global adiposity with clinical relevance including BMI and percentage body fat, as well as regional markers of adiposity with clinical relevance including waist circumference, waist-to-hip ratio, sagittal abdominal diameter, and visceral adipose tissue [VAT] by imaging modalities.

Data synthesis: Pooled analysis will be conducted using the Generic Inverse Variance method. Separate analyses will be conducted for children and adults. Analyses will be further stratified by metabolic phenotype (normal weight, overweight/obese, metabolic syndrome criteria, diabetes, etc.). Random-effects models will be used even in the absence of statistically significant between-study heterogeneity, as they yield more conservative summary effect estimates in the presence of residual heterogeneity. Fixed-effects models will only be used where there is <5 included studies. Paired analyses will be applied to all crossover trials. Heterogeneity will be tested by the Cochran Q statistic and quantified by the I2 statistic. Sources of heterogeneity will be explored by sensitivity and subgroup analyses. If there are ≥ 10 trial comparisons, then a priori subgroup analyses will also be conducted by dose (<100g/day, ≥100g/day), comparator, follow-up (<6-months, ≥6-months), baseline body weight (BMI ≤25 >25kg/m2), design (parallel, crossover), energy balance (negative, neutral, positive), GI (absolute level [≤55, >55], within-treatment change, between-treatment change), fat intake (absolute level [<30%, ≥30% energy], within-treatment change, between-treatment change), carbohydrate intake (absolute level [<50%, ≥50% energy], within-treatment change, between-treatment change), protein intake (absolute level [<20%, ≥20% energy], within-treatment change, between-treatment change), dietary fibre intake (absolute level [<25g/day, ≥25g/day], within-treatment change, between-treatment change), and risk of bias. Meta-regression will assess the significance of categorical and continuous subgroup analyses. Non-linear relationships will be assessed by spline curve modeling (the MKSPLINE procedure) to assess whether there is a threshold for benefit. If there are ≥10 trial comparisons, then publication bias will be assessed by inspection of funnel plots and the Egger and Begg tests. In the presence of significant publication bias, an adjustment for funnel plot asymmetry will be attempted by using the Duval and Tweedie trim-and-fill method.

Evidence Assessment: The strength of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Knowledge translation plan: Results will be disseminated through traditional means such as interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Innovative means such as webcasts with e-mail feedback mechanisms will also be used. Knowledge Users will act as knowledge brokers networking among opinion leaders and different adopter groups to increase awareness at each stage. Four Knowledge Users will also participate directly as members of nutrition guidelines committees. Target adopters will include the clinical practice, public health, industry, research communities, and patient groups. Feedback will be incorporated and used to guide analyses and improve key messages at each stage.

Significance: The proposed project will aid in knowledge translation related to the role of pasta as part of a healthy low-GI-dietary pattern on health outcomes strengthening the evidence-base for guidelines and improving health outcomes, by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.

Being tested
Pasta as part of a low GI/GL diet
Keywords
Systematic review and meta-analysis, Evidence-based medicine (EBM), Evidence-based nutrition (EBN), Clinical practice guidelines, Glycemic index, Pasta, Glycemic load, Body weight, Cardiovascular risk factors, Cardiovascular disease
Medical subject headings
Diabetes Mellitus, Prediabetic State, Overweight, Obesity, Metabolic Syndrome, Cardiovascular Diseases, Body Weight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pasta as part of a low GI/GL dietOther

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Global measures of adiposity with established clinical relevance - body weight

    body weight

    Measured: Up to 20 years

Secondary outcomes (6)
  1. Global measures of adiposity with established clinical relevance - BMI

    body mass index, BMI

    Measured: Up to 20 years

  2. Global measures of adiposity with established clinical relevance - percentage body fat

    percentage body fat

    Measured: Up to 20 years

  3. Regional measures of adiposity with established clinical relevance - waist circumference

    waist circumference

    Measured: Up to 20 years

  4. Regional measures of adiposity with established clinical relevance - waist-to-hip ratio

    waist-to-hip ratio

    Measured: Up to 20 years

  5. Regional measures of adiposity with established clinical relevance - sagittal abdominal diameter

    sagittal abdominal diameter

    Measured: Up to 20 years

  6. Measures of adiposity by established imaging techniques - visceral adipose tissue [VAT]

    visceral adipose tissue [VAT] by imaging modalities

    Measured: Up to 20 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Nov 2016 (estimated)
  2. Study startAug 2016
  3. Primary completionAug 2017 (estimated)
  4. Study completionAug 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
1 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02961088
Sponsor's protocol ID
Toronto3D Pasta 2016
Status last verified
Nov 2016
First submitted
4 Nov 2016
Last updated
17 Nov 2016
Results posted
No
Data monitoring committee
No
Individual data sharing
No: All data will be included in the meta-analyses and available online as supplemental material

Publications

  • Mirrahimi A, de Souza RJ, Chiavaroli L, Sievenpiper JL, Beyene J, Hanley AJ, Augustin LS, Kendall CW, Jenkins DJ. Associations of glycemic index and load with coronary heart disease events: a systematic review and meta-analysis of prospective cohorts. J Am Heart Assoc. 2012 Oct;1(5):e000752. doi: 10.1161/JAHA.112.000752. Epub 2012 Oct 25.

    PubMed 23316283
  • Turner-McGrievy GM, Jenkins DJ, Barnard ND, Cohen J, Gloede L, Green AA. Decreases in dietary glycemic index are related to weight loss among individuals following therapeutic diets for type 2 diabetes. J Nutr. 2011 Aug;141(8):1469-74. doi: 10.3945/jn.111.140921. Epub 2011 Jun 8.

    PubMed 21653575
  • Larsen TM, Dalskov SM, van Baak M, Jebb SA, Papadaki A, Pfeiffer AF, Martinez JA, Handjieva-Darlenska T, Kunesova M, Pihlsgard M, Stender S, Holst C, Saris WH, Astrup A; Diet, Obesity, and Genes (Diogenes) Project. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med. 2010 Nov 25;363(22):2102-13. doi: 10.1056/NEJMoa1007137.

    PubMed 21105792
  • Jenkins DJ, Kendall CW, Augustin LS, Mitchell S, Sahye-Pudaruth S, Blanco Mejia S, Chiavaroli L, Mirrahimi A, Ireland C, Bashyam B, Vidgen E, de Souza RJ, Sievenpiper JL, Coveney J, Leiter LA, Josse RG. Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med. 2012 Nov 26;172(21):1653-60. doi: 10.1001/2013.jamainternmed.70.

    PubMed 23089999
  • Chiavaroli L, Kendall CWC, Braunstein CR, Blanco Mejia S, Leiter LA, Jenkins DJA, Sievenpiper JL. Effect of pasta in the context of low-glycaemic index dietary patterns on body weight and markers of adiposity: a systematic review and meta-analysis of randomised controlled trials in adults. BMJ Open. 2018 Apr 2;8(3):e019438. doi: 10.1136/bmjopen-2017-019438.

    PubMed 29615407

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes and Prediabetes, run by University of Toronto.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Global measures of adiposity with established clinical relevance - body weight (time frame: Up to 20 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02961088, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in